3 years ago

Differential expression of PD-L1 between sporadic and VHL-associated hereditary clear cell renal cell carcinoma and its correlation with clinicopathological features

Baoan Hong, Lin Cai, Jiangyi Wang, Shengjie Liu, Jingcheng Zhou, Kaifang Ma, Jiufeng Zhang, Bowen Zhou, Xiang Peng, Ning Zhang, Kan Gong

Publication date: Available online 13 November 2018

Source: Clinical Genitourinary Cancer

Author(s): Baoan Hong, Lin Cai, Jiangyi Wang, Shengjie Liu, Jingcheng Zhou, Kaifang Ma, Jiufeng Zhang, Bowen Zhou, Xiang Peng, Ning Zhang, Kan Gong

Abstract

Programmed death ligand-1 (PD-L1) inhibitor is an effective immunotherapy in the treatment of solid tumors. The expression of PD-L1 was evaluated in sporadic and VHL-associated hereditary clear cell renal cell carcinoma (ccRCC). Positive PD-L1 expression is associated with aggressive clinicopathological features not only in sporadic ccRCC but also in VHL-associated hereditary ccRCC. It provides a valuable consultation for clinical treatment.

Background

PD-L1 is a potential predictive biomarker for immunotherapy in several malignancies. However, the expression level and clinical significance of PD-L1 in VHL-associated hereditary ccRCC remain unclear.

Methods

Surgical specimens were recruited from 129 patients with sporadic ccRCC and 26 patients with VHL-associated hereditary ccRCC. The PD-L1 expression level was assessed by immunohistochemistry. Correlations between PD-L1 expression and clinicopathological features were analyzed.

Results

In sporadic ccRCC, positive expression rate of PD-L1 was 47.3%. Positive PD-L1 expression was correlated with advanced tumor T stage (P = 0.011), higher Fuhrman nuclear grade (P = 0.022), poor disease-free survival (DFS) (P = 0.037) and gender (P = 0.025). In the VHL-associated hereditary ccRCC, positive PD-L1 expression rate was 34.6%, lower than that in sporadic ccRCC. Positive PD-L1 was correlated with higher Fuhrman nuclear grade (P = 0.008), but not with gender, age, tumor stage, or the onset age of VHL-associated tumors.

Conclusion

Positive PD-L1 expression was correlated with the aggressive clinicopathological features both in sporadic and VHL-associated hereditary ccRCC. Whether PD-L1 expression level in ccRCC is related to the effectiveness of PD-1/PD-L1 checkpoint inhibitor immunotherapy needs to be further investigated.

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.